ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,461 to 4,480 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Video Laryngoscope Group vs Direct Laryngoscope Group: deaths from any cause184 of 705

191 of 712

-0.7 points

-5.3 to 3.9

1,417NCT05239195

DirEct Versus VIdeo LaryngosCopE Trial

Video Laryngoscope Group vs Direct Laryngoscope Group: Esophageal Intubation6 of 705

9 of 712

-0.4 points

-1.6 to 0.7

1,417NCT05239195

DirEct Versus VIdeo LaryngosCopE Trial

AZD7442 Plus SOC vs Placebo Plus SOC: Number of Participants With Sustained Recovery617 of 710

594 of 707

2.9 points

-0.8 to 6.6

1,417NCT05780437

AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

AZD7442 Plus SOC vs Placebo Plus SOC: Number of Participants With a Safety Outcome Through Day 28226 of 710

250 of 707

-3.5 points

-8.4 to 1.4

1,417NCT05780437

AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

AZD7442 Plus SOC vs Placebo Plus SOC: Number of Participants Who Died From All Causes61 of 710

86 of 707

-3.6 points

-6.8 to -0.4

1,417NCT05780437

AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

AZD7442 Plus SOC vs Placebo Plus SOC: deaths from any cause61 of 710

86 of 707

-3.6 points

-6.8 to -0.4

1,417NCT05780437

AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

AZD7442 Plus SOC vs Placebo Plus SOC: Number of Participants With a Safety Outcome Through Day 90179 of 710

214 of 707

-5.1 points

-9.7 to -0.4

1,417NCT05780437

AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

AZD7442 Plus SOC vs Placebo Plus SOC: Number of Participants With a Safety Outcome Through Day 5181 of 710

202 of 707

-3.1 points

-7.7 to 1.5

1,417NCT05780437

AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

AZD7442 Plus SOC vs Placebo Plus SOC: serious adverse events36 of 710

39 of 707

-0.4 points

-2.8 to 1.9

1,417NCT05780437

AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

ZD4054 vs Placebo: serious adverse events148 of 703

138 of 712

1.7 points

-2.5 to 5.9

1,415NCT00626548

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer

Distress Screening vs No Screening: Number of Patients With Oncology Visit728 of 730

683 of 683

-0.3 points

-1.0 to 0.3

1,413NCT02941614

Implementing Systematic Distress Screening in Breast Cancer

Distress Screening vs No Screening: Number of Participants Utilizing Behavioral Health Services287 of 730

247 of 683

3.2 points

-1.9 to 8.2

1,413NCT02941614

Implementing Systematic Distress Screening in Breast Cancer

Distress Screening vs No Screening: Number of Patients With Primary Care Visit648 of 730

616 of 683

-1.4 points

-4.6 to 1.8

1,413NCT02941614

Implementing Systematic Distress Screening in Breast Cancer

Bundles vs Bundles and Discount: Number of Participants Who Kept Healthy Bundle Default Shopping Cart Items in Basket at Purchase679 of 727

655 of 686

-2.1 points

-4.5 to 0.3

1,413NCT04766034

Impact of Behavioral Economic Strategies on Low-Income Older Adults' Food Choices in Online Retail Settings

Influenza Virus Vaccine (Pooled) vs Comparator Influenza Vaccine: serious adverse events11 of 1,209

4 of 202

-1.1 points

-4.1 to 0.3

1,411NCT00617851

Study to Evaluate the Consistency of Three Consecutive Production Lots of Influenza Vaccine in Healthy Subjects 18 to 49 Years Old

Transitional Tobacco Care Management (TTCM) vs eReferral to State Tobacco Quitline (QL): Tobacco Abstinence, Self-report276 of 706

218 of 703

8.1 points

3.1 to 13.0

1,409NCT03603496

Post-Discharge Smoking Cessation Strategies: Helping HAND 4

Transitional Tobacco Care Management (TTCM) vs eReferral to State Tobacco Quitline (QL): Engagement in Cessation Treatment434 of 706

319 of 703

16.1 points

10.9 to 21.2

1,409NCT03603496

Post-Discharge Smoking Cessation Strategies: Helping HAND 4

Transitional Tobacco Care Management (TTCM) vs eReferral to State Tobacco Quitline (QL): Tobacco Abstinence, Self-report234 of 706

202 of 703

4.4 points

-0.4 to 9.2

1,409NCT03603496

Post-Discharge Smoking Cessation Strategies: Helping HAND 4

Transitional Tobacco Care Management (TTCM) vs eReferral to State Tobacco Quitline (QL): Tobacco Abstinence, Self-report291 of 706

246 of 703

6.2 points

1.2 to 11.3

1,409NCT03603496

Post-Discharge Smoking Cessation Strategies: Helping HAND 4

Transitional Tobacco Care Management (TTCM) vs eReferral to State Tobacco Quitline (QL): Engagement in Cessation Treatment489 of 706

369 of 703

16.8 points

11.7 to 21.7

1,409NCT03603496

Post-Discharge Smoking Cessation Strategies: Helping HAND 4

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=224"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=224

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT05239195-deaths",
        "title": "Video Laryngoscope Group vs Direct Laryngoscope Group: deaths from any cause",
        "summary": "184 of 705 against 191 of 712; risk difference -0.7 points, 95% interval -5.3 to 3.9; NCT05239195, DirEct Versus VIdeo LaryngosCopE Trial",
        "record": "/library/comparisons/NCT05239195-deaths",
        "nct_id": "NCT05239195",
        "kind": "deaths",
        "participants": 1417,
        "risk_difference": {
          "value": -0.007265519164873724,
          "lower": -0.05311381112068955,
          "upper": 0.03864893916815562
        },
        "group_1": "184 of 705",
        "group_2": "191 of 712",
        "difference": "-0.7 points",
        "interval": "-5.3 to 3.9",
        "trial_title": "DirEct Versus VIdeo LaryngosCopE Trial"
      },
      {
        "id": "NCT05239195-fffa50ba",
        "title": "Video Laryngoscope Group vs Direct Laryngoscope Group: Esophageal Intubation",
        "summary": "6 of 705 against 9 of 712; risk difference -0.4 points, 95% interval -1.6 to 0.7; NCT05239195, DirEct Versus VIdeo LaryngosCopE Trial",
        "record": "/library/comparisons/NCT05239195-fffa50ba",
        "nct_id": "NCT05239195",
        "kind": "outcome",
        "participants": 1417,
        "risk_difference": {
          "value": -0.004129811140329906,
          "lower": -0.016245786697620463,
          "upper": 0.0074612120071021835
        },
        "group_1": "6 of 705",
        "group_2": "9 of 712",
        "difference": "-0.4 points",
        "interval": "-1.6 to 0.7",
        "trial_title": "DirEct Versus VIdeo LaryngosCopE Trial"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=225",
  "request_id": "L09nI5nz03qgZMC1"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

Instruments

The conductscience.com catalog

One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.

Drugs and targets

Open Targets

One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.

Diseases

Open Targets

One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.

Companies

ClinicalTrials.gov

One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.

Cell lines

Cellosaurus

One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.

Journal index

PubMed and NLM's journal list

One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?